PERBANDINGAN EFEKTIVITAS BIAYA PEMBERIAN OBAT SEFTRIAKSON DAN LEVOFLOKSASIN PADA PASIEN PNEUMONIA DEWASA DI INSTALASI RAWAT INAP RSPAD GATOT SOEBROTO
Pneumonia is a respiratory infection that affects 450 million people and kills 7% of them worldwide. It is a major problem in Indonesia, especially Jakarta, where 2.2% of the population had pneumonia in 2021. Levofloxacin and ceftriaxone are common antibiotics for pneumonia. This study compares thei...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
2024-01-09.
|
| Subjects: | |
| Online Access: | Link Metadata |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | repoupnvj_28281 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Muhamad Iqbal Husaini, . |e author |
| 245 | 0 | 0 | |a PERBANDINGAN EFEKTIVITAS BIAYA PEMBERIAN OBAT SEFTRIAKSON DAN LEVOFLOKSASIN PADA PASIEN PNEUMONIA DEWASA DI INSTALASI RAWAT INAP RSPAD GATOT SOEBROTO |
| 260 | |c 2024-01-09. | ||
| 500 | |a http://repository.upnvj.ac.id/28281/2/ABSTRAK.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/12/AWAL.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/3/BAB%201.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/4/BAB%202.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/5/BAB%203.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/6/BAB%204.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/7/BAB%205.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/8/DAFTAR%20PUSTAKA.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/9/RIWAYAT%20HIDUP.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/10/LAMPIRAN.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/11/HASIL%20PLAGIARISME.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/28281/1/ARTIKEL%20KI.pdf | ||
| 520 | |a Pneumonia is a respiratory infection that affects 450 million people and kills 7% of them worldwide. It is a major problem in Indonesia, especially Jakarta, where 2.2% of the population had pneumonia in 2021. Levofloxacin and ceftriaxone are common antibiotics for pneumonia. This study compares their cost-effectiveness using a cross-sectional observational analysis of medical data and patient costs from January 2022 to September 2023. Ceftriaxone therapy was cheaper but not significantly different from levofloxacin therapy (p = 0.944). Levofloxacin reduced leukocytes more than ceftriaxone (p = 0.033). Levofloxacin therapy had a lower ACER value of IDR 1,410.58 than ceftriaxone therapy. Switching from ceftriaxone to levofloxacin cost IDR 64.00 more per 1 μL leukocyte reduction. Levofloxacin was more cost-effective than ceftriaxone for pneumonia patients at RSPAD Gatot Soebroto. | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 690 | |a R Medicine (General) | ||
| 690 | |a RM Therapeutics. Pharmacology | ||
| 690 | |a RS Pharmacy and materia medica | ||
| 655 | 7 | |a Thesis |2 local | |
| 655 | 7 | |a NonPeerReviewed |2 local | |
| 787 | 0 | |n http://repository.upnvj.ac.id/28281/ | |
| 856 | 4 | 1 | |u http://repository.upnvj.ac.id/28281/ |z Link Metadata |